When disease extent is not always a key parameter: Management of refractory ulcerative proctitis

Q2 Agricultural and Biological Sciences Current Research in Pharmacology and Drug Discovery Pub Date : 2022-01-01 DOI:10.1016/j.crphar.2021.100071
Georgios Michalopoulos , Konstantinos Karmiris
{"title":"When disease extent is not always a key parameter: Management of refractory ulcerative proctitis","authors":"Georgios Michalopoulos ,&nbsp;Konstantinos Karmiris","doi":"10.1016/j.crphar.2021.100071","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Patients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases.</p></div><div><h3>Objectives</h3><p>To summarize available evidence on the management of refractory ulcerative proctitis and provide insights in treatment options.</p></div><div><h3>Results</h3><p>/Conclusion: Topical therapy plays a central role due to the location of the disease. However, well-established treatment options may become exhausted in a considerable proportion of ulcerative proctitis patients, indicating the need to advance to more potent therapies in order to induce and maintain clinical response and remission in these refractory cases. Systemic corticosteroids, thiopurines, calcineurin inhibitors, biologic agents and small molecules have all been tested with variable success rates. Investigational interventions as well as surgical procedures are kept as the ultimate resort in multi-treatment resistant cases. Identifying early prognostic factors that herald a disabling disease progression will help in optimizing treatment and avoiding surgery.</p></div>","PeriodicalId":10877,"journal":{"name":"Current Research in Pharmacology and Drug Discovery","volume":"3 ","pages":"Article 100071"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/ee/main.PMC8695253.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Pharmacology and Drug Discovery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590257121000584","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Agricultural and Biological Sciences","Score":null,"Total":0}
引用次数: 1

Abstract

Background

Patients with ulcerative proctitis represent a sub-group of ulcerative colitis patients with specific characteristics. Disease-related symptoms, endoscopic findings and patient's personality perspectives create a difficult-to-assess condition in certain cases.

Objectives

To summarize available evidence on the management of refractory ulcerative proctitis and provide insights in treatment options.

Results

/Conclusion: Topical therapy plays a central role due to the location of the disease. However, well-established treatment options may become exhausted in a considerable proportion of ulcerative proctitis patients, indicating the need to advance to more potent therapies in order to induce and maintain clinical response and remission in these refractory cases. Systemic corticosteroids, thiopurines, calcineurin inhibitors, biologic agents and small molecules have all been tested with variable success rates. Investigational interventions as well as surgical procedures are kept as the ultimate resort in multi-treatment resistant cases. Identifying early prognostic factors that herald a disabling disease progression will help in optimizing treatment and avoiding surgery.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
当疾病程度不总是一个关键参数:难治性溃疡性直肠炎的处理
背景溃疡性直肠炎患者是溃疡性结肠炎患者的一个亚组,具有特定的特征。在某些情况下,疾病相关症状、内窥镜检查结果和患者的个性观点造成了难以评估的状况。目的总结难治性溃疡性直肠炎治疗的现有证据,为治疗方案提供参考。结果/结论:局部治疗因其病变部位而起核心作用。然而,在相当一部分溃疡性直肠炎患者中,完善的治疗方案可能会耗尽,这表明需要推进更有效的治疗,以诱导和维持这些难治性病例的临床反应和缓解。全身皮质类固醇、硫嘌呤、钙调磷酸酶抑制剂、生物制剂和小分子药物都进行了测试,成功率各不相同。调查干预和外科手术仍然是多重治疗耐药病例的最终手段。识别预示致残疾病进展的早期预后因素将有助于优化治疗和避免手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Current Research in Pharmacology and Drug Discovery
Current Research in Pharmacology and Drug Discovery Agricultural and Biological Sciences-Animal Science and Zoology
CiteScore
6.40
自引率
0.00%
发文量
65
审稿时长
40 days
期刊最新文献
Editorial Board Table of Contents Development of Recombinant Antibody by Yeast Surface Display Technology Papaverine attenuates the progression of alpha naphthylisothiocyanate induce cholestasis in rats Long-term effects of neonatal pain and sucrose treatment
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1